OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Technology & Therapeutics is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology	150
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users	137
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes	131
Racial–Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes	103
Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology	97
The Digital/Virtual Diabetes Clinic: The Future Is Now—Recommendations from an International Panel on Diabetes Digital Technologies Introduction	86
A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System	82
Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic	74
The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes	71
Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes	63
Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial	63
Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes	62
Adoption of Telemedicine for Type 1 Diabetes Care During the COVID-19 Pandemic	54
First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes	54
Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes	54
A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense Continuous Glucose Monitoring Devices in a Home-Use Study of Subjects with Type 1 Diabetes	54
HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis	52
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study	50
Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Ov	49
The Effectiveness of Virtual Training on the MiniMed™ 670G System in People with Type 1 Diabetes During the COVID-19 Pandemic	47
Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes	46
Implicit Racial–Ethnic and Insurance-Mediated Bias to Recommending Diabetes Technology: Insights from T1D Exchange Multicenter Pediatric and Adult Diabetes Provider Cohort	45
Top 10 Tips for Successfully Implementing a Diabetes Telehealth Program	45
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes	45
Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features	44

Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and Their Parents	43
M♡THer, an mHealth System to Support Women with Gestational Diabetes Mellitus: Feasibility and Acceptability Study	41
Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System	40
Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study	37
Current Status and Emerging Options for Automated Insulin Delivery Systems	37
Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and Preschoolers	37
Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring	36
Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial	36
Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement Collaborative	36
“I Didn't Really Have a Choice”: Qualitative Analysis of Racial-Ethnic Disparities in Diabetes Technology Use Among Young Adults with Type 1 Diabetes	36
Fast-Acting Insulin Aspart Use with the MiniMed^TM 670G System	35